Economic impact of tobramycin in patients with cystic fibrosis in a managed care population

References

• Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry: 2007 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation, 2007
   Google Scholar
• Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic edications for maintenance of lung health. Am J Respir Crit Care Med 2007;176:957-69
   PubMed Web of Science ®Google Scholar
• TOBI® (tobramycin inhalation solution) [package insert]. East Hanover, NJ: Novrtis Pharmaceuticals Corporation, 2008
   Google Scholar
• Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30
   PubMed Web of Science ®Google Scholar
• Burns JL, Van Dalfsen JM, Shawar RM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999;179:1190-6
   PubMed Web of Science ®Google Scholar
• MacLuskey IB, Gold R, Corey M, et al. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 1989;7:42-8
   PubMedGoogle Scholar
• Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-6
   PubMed Web of Science ®Google Scholar
• Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care 2003;168:918-51
   PubMed Web of Science ®Google Scholar
• Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100
   PubMed Web of Science ®Google Scholar
• Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001;138:699-704
   PubMed Web of Science ®Google Scholar
• Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol 1995;48:1041-9
   PubMed Web of Science ®Google Scholar
• Liou TG, Adler FR, FitzSimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-52
   PubMed Web of Science ®Google Scholar
• Abbott J, Dodd M, Bilton D, et al. Treatment compliance in adults with cystic fibrosis. Thorax 1994;49:115-20
   PubMed Web of Science ®Google Scholar
• Sacket DL, Snow JC. The magnitude of compliance and non-compliance. In: Hayes RB, Taylor WB, Sacket DL, eds. Compliance in healthcare. Baltimore, MD: John Hopkins University Press, 1977. p 11-22
   Google Scholar
• Conway SP, Pond MN, Hamnett T, et al. Compliance with treatment in adult patients with cystic fibrosis. Thorax 1996;51:29-33
   PubMed Web of Science ®Google Scholar
• Briesacher BA, Quittner A, Saiman L, et al. Adherence to tobramycin inhaled solution and health care utilization [abstract]. Am J Respir Crit Care Med 2009;179:A1183
   Web of Science ®Google Scholar
• Van Devanter DR, O’Riordan MA, Blumer JL, et al. Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respir Res 2010;11:137
   PubMed Web of Science ®Google Scholar
• Flume PA, Mogayzel PJ, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802-8
   PubMed Web of Science ®Google Scholar
• Blumer JL, Saiman L, Konstan MW, et al. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 2005;128:2336-46
   PubMed Web of Science ®Google Scholar
• Ratjen F, Munck A, Kho P, et al. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010;65:286-91
   PubMed Web of Science ®Google Scholar
• Treggiari MM, Rosenfeld M, Mayer-Hamblett N, et al. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp Clin Trials 2009;30:256-68
   PubMed Web of Science ®Google Scholar
• Wiesemann HG, Steinkamp G, Ratjen F, et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998;25:88-92
   PubMed Web of Science ®Google Scholar
• O’Sullivan A, Sullivan JK, Higuchi K. Medication compliance and impact on health-care resource utilization and mortality among cystic fibrosis patients with P aeruginosa. [abstract] Pediatr Pulmonol 2008;43(S31):A584
   PubMedGoogle Scholar
• Ouyang L, Grosse SD, Amendah DD, et al. Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol 2009;44:989-96
   PubMed Web of Science ®Google Scholar
• Lieu TA, Ray GT, Farmer G, et al. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics 1999;103:e72
   PubMed Web of Science ®Google Scholar
• Baumann U, Stocklossa C, Greiner W, et al. Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros 2003;2:84-90
   PubMedGoogle Scholar
• O’Sullivan AK, Sullivan JM, Higuchi K. Health-care utilization and costs evaluation of pediatric and adult patients with cystic fibrosis treated for pulmonary manifestations. [abstract] Pediatr Pulmonol 2008;43(S31):A583
   Google Scholar
• Briesacher BA, Quittner AL, Saiman L, Sacco P, Fouayzi H, Quittell LM. Adherence with tobramycin inhaled solution and health care utilization. BMC Pulmonary Medicine 2011;11:5, doi:10.1186/1471-2466-11-5
   Google Scholar